Serum insulin-like growth factor I and ischemic brain injury

Brain Research

Volumn 1185, Issue 1, 2007, Pages 328-335

  Endres, Matthias ^a   Piriz, Joaquin ^b   Gertz, Karen ^a   Harms, Christoph ^a   Meisel, Andreas ^a   Kronenberg, Golo ^a   Torres Aleman, Ignacio ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INSTITUTO CAJAL   (Spain)

Author keywords

Aging; Insulin like growth factor 1; Mice; Middle cerebral artery occlusion; Stroke

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; MIDDLE CEREBRAL ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROKE;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN INJURIES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INFARCTION, MIDDLE CEREBRAL ARTERY; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE KINASES;

MAMMALIA; MUS;

EID: 36448946874     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.09.053     Document Type: Article

References (45)

1. Alessandrini A., Namura S., Moskowitz M.A., and Bonventre J.V. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12866-12869
2. Armstrong C.S., Wuarin L., and Ishii D.N. Uptake of circulating insulin-like growth factor-I into the cerebrospinal fluid of normal and diabetic rats and normalization of IGF-II mRNA content in diabetic rat brain. J. Neurosci. Res. 59 (2000) 649-660
3. Beilharz E.J., Russo V.C., Butler G., Baker N.L., Connor B., Sirimanne E.S., Dragunow M., Werther G.A., Gluckman P.D., Williams C.E., and Scheepens A. Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury. Brain Res. Mol. Brain Res. 59 (1998) 119-134
4. Blair L.A., and Marshall J. IGF-1 modulates N and L calcium channels in a PI 3-kinase-dependent manner. Neuron 19 (1997) 421-429
5. Busiguina S., Fernandez A.M., Barrios V., Clark R., Tolbert D.L., Berciano J., and Torres-Aleman I. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol. Dis. 7 (2000) 657-665
6. Carrascosa C., Torres-Aleman I., Lopez-Lopez C., Carro E., Espejo L., Torrado S., and Torrado J.J. Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration. Biomaterials 25 (2004) 707-714
7. Carrascosa C., Torres-Aleman I., Lopez-Lopez C., Carro E., Espejo L., Torrado S., and Torrado J.J. Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration. Biomaterials 25 (2004) 707-714
8. Carro E., Nunez A., Busiguina S., and Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 20 (2000) 2926-2933
9. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., and Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8 (2002) 1390-1397
10. Carro E., Trejo J.L., Nunez A., and Torres-Aleman I. Brain repair and neuroprotection by serum insulin-like growth factor I. Mol. Neurobiol. 27 (2003) 153-162
11. Coschigano K.T., Holland A.N., Riders M.E., List E.O., Flyvbjerg A., and Kopchick J.J. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144 (2003) 3799-3810
12. Denti L., Annoni V., Cattadori E., Angela Salvagnini M., Visioli S., Francesca Merli M., Corradi F., Ceresini G., Valenti G., Hoffman A.R., and Paolo C.G. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am. J. Med. 117 (2004) 312-317
13. Deuschle M., Blum W.F., Strasburger C.J., Schweiger U., Weber B., Korner A., Standhardt H., Gotthardt U., Schmider J., Pflaum C.D., and Heuser I. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 22 (1997) 493-503
14. Endres M., Gertz K., Lindauer U., Katchanov J., Schultze J., SChröck H., Kuschinksy W., Dirnagl U., and Laufs U. Mechanisms of stroke protection by physical activity. Ann. Neurol. 54 (2003) 582-590
15. Flurkey K., Papaconstantinou J., Miller R.A., and Harrison D.E. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6736-6741
16. Guan J., Bennet L., Gluckman P.D., and Gunn A.J. Insulin-like growth factor-1 and post-ischemic brain injury. Prog. Neurobiol. 70 (2003) 443-462
17. Guan J., Williams C.E., Skinner S.J., Mallard E.C., and Gluckman P.D. The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Endocrinology 137 (1996) 893-898
18. Holzenberger M., Dupont J., Ducos B., Leneuve P., Geloen A., Even P.C., Cervera P., and Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421 (2003) 182-187
19. Ikeno Y., Bronson R.T., Hubbard G.B., Lee S., and Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J. Gerontol., A, Biol. Sci. Med. Sci. 58 (2003) 291-296
20. Ivanusa M., and Ivanusa Z. Risk factors and in-hospital outcomes in stroke and myocardial infarction patients. BMC Public Health 4 (2004) 26
21. Johnston B.M., Mallard E.C., Williams C.E., and Gluckman P.D. Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs. J. Clin. Invest. 97 (1996) 300-308
22. Katchanov J., Harms C., Gertz K., Hauck L., Waeber C., Hirt L., Priller J., von Harsdorf R., Bruck W., Hortnagl H., Dirnagl U., Bhide P.G., and Endres M. Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J. Neurosci. 21 (2001) 5045-5053
23. Katchanov J., Waeber C., Gertz K., Gietz A., Winter B., Bruck W., Dirnagl U., Veh R.W., and Endres M. Selective neuronal vulnerability following mild focal brain ischemia in the mouse. Brain Pathol. 13 (2003) 452-464
24. Leifke E., Gorenoi V., Wichers C., Von Zur M.A., Von Buren E., and Brabant G. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin. Endocrinol. (Oxf.) 53 (2000) 689-695
25. LeRoith D., Werner H., Beitner-Johnson D., and Roberts Jr. C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16 (1995) 143-163
26. Lopez-Lopez C., LeRoith D., and Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9833-9838
27. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., Hideshima T., Chauhan D., Joseph M., Libermann T.A., Garcia-Echeverria C., Pearson M.A., Hofmann F., Anderson K.C., and Kung A.L. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cells 5 (2004) 221-230
28. Mustafa A., Lannfelt L., Lilius L., Islam A., Winblad B., and Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement. Geriatr Cogn Disord. 10 (1999) 446-451
29. Nam R.K., Trachtenberg J., Jewett M.A., Toi A., Evans A., Emami M., Narod S.A., and Pollak M. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between igf-I physiology and prostate cancer risk. Cancer Epidemiol. Biomark. Prev. 14 (2005) 1270-1273
30. Nozaki K., Nishimura M., and Hashimoto N. Mitogen-activated protein kinases and cerebral ischemia. Mol. Neurobiol. 23 (2001) 1-19
31. Nunez A., Carro E., and Torres-Aleman I. Insulin-like growth factor I modifies electrophysiological properties of rat brain stem neurons. J. Neurophysiol. 89 (2003) 3008-3017
32. Pardridge W.M. Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann. N.Y. Acad. Sci. 692 (1993) 126-137
33. Pons S., and Torres-Aleman I. Basic fibroblast growth factor modulates insulin-like growth factor-I, its receptor, and its binding proteins in hypothalamic cell cultures. Endocrinology 131 (1992) 2271-2278
34. Ranke M.B., Osterziel K.J., Schweizer R., Schuett B., Weber K., Robbel P., Vornwald A., Blumenstock G., and Elmlinger M.W. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays. Clin. Chem. Lab. Med. 41 (2003) 1329-1334
35. Reinhardt R.R., and Bondy C.A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 135 (1994) 1753-1761
36. Ruscher K., Freyer D., Karsch M., Isaev N., Megow D., Sawitzki B., Priller J., Dirnagl U., and Meisel A. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J. Neurosci. 22 (2002) 10291-10301
37. Schabitz W.R., Hoffmann T.T., Heiland S., Kollmar R., Bardutzky J., Sommer C., and Schwab S. Delayed neuroprotective effect of insulin-like growth factor-I after experimental transient focal cerebral ischemia monitored with MRI. Stroke 32 (2001) 1226-1233
38. Schwab S., Spranger M., Krempien S., Hacke W., and Bettendorf M. Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury. Stroke 28 (1997) 1744-1748
39. Strasburger C.J., Bidlingmaier M., Wu Z., and Morrison K.M. Normal values of insulin-like growth factor I and their clinical utility in adults. Horm. Res. 55 Suppl 2 (2001) 100-105
40. Tham A., Nordberg A., . Grissom F.E., Carlsson-Skwirut C., Viitanen M., and Sara V.R. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J. Neural Transm., Parkinson's Dis. Dement. Sect. 5 (1993) 165-176
41. Torres-Aleman I. Serum growth factors and neuroprotective surveillance. Mol. Neurobiol. 21 (2000) 153-160
42. Torres-Aleman I., Barrios V., Lledo A., and Berciano J. The insulin-like growth factor I system in cerebellar degeneration. Ann. Neurol. 39 (1996) 335-342
43. Torres-Aleman I., Barrios V., and Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 50 (1998) 772-776
44. Trejo J.L., Carro E., Garcia-Galloway E., and Torres-Aleman I. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J. Mol. Med. 2 (2004) 156-162
45. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., and LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7324-7329